Retrogenix Company Overview and Achievements

Retrogenix is a UK-based company that's making waves in the field of 3D cell culture and organoid technology. Founded in 2011, the company has been at the forefront of developing innovative solutions for drug discovery and development.

Retrogenix's expertise lies in creating 3D cell cultures that mimic the complexity of human tissues, allowing researchers to study disease mechanisms and test potential treatments in a more accurate and relevant way. This technology has the potential to revolutionize the way we approach drug development.

With a strong focus on innovation and collaboration, Retrogenix has established partnerships with leading pharmaceutical companies and research institutions to advance the field of 3D cell culture and organoid technology. By working together, Retrogenix is helping to accelerate the discovery of new treatments and improve patient outcomes.

Retrogenix is a biotechnology company based in the United Kingdom. Founded in 2007, Retrogenix has been at the forefront of developing innovative solutions for the discovery and validation of therapeutic antibodies.

The company's expertise lies in its ability to provide high-quality, bespoke antibody discovery and validation services to pharmaceutical and biotechnology companies.

Retrogenix's services include the discovery of new antibodies, as well as the validation of existing ones to ensure their effectiveness in treating various diseases.

For another approach, see: GE Capital Aviation Services

Retrogenix has been recognized for its achievements through various awards. They have received the Queen's Awards for Enterprise.

The first award was granted for innovation in 2015. This was a significant milestone for the company.

Retrogenix has also been recognized for its international trade efforts. They received the Queen's Award for Enterprise for international trade in 2017.

Here are the details of the awards Retrogenix has received:

Retrogenix is a company that's making waves in the field of biotechnology.

The company is working with a consortium that includes Phenotox Ltd, Retrogenix Ltd, and Sheffield Hallam University to develop a platform that's ready for larger scale studies against 500-1000 targets.

This collaboration has the support of CRACK IT Solutions funding, which is a significant boost to the project.

Biogen, a US-based company, is also on board to further develop the technical aspects of the platform.

The goal is to have the platform ready for adoption by end users, which could revolutionize the way we approach certain tasks.

Charles River Laboratories has made a significant move in the industry with the acquisition of Retrogenix.

Charles River's acquisition of Retrogenix adds a proprietary cell microarray technology to their existing discovery capabilities, allowing for accelerated target identification and preclinical safety assurance for novel therapies.

This strategic move enhances Charles River's ability to support clients' early-stage drug research efforts in advanced drug modalities, including cell therapies.

Retrogenix offers a large protein library with more than 6,200 human plasma membrane and secreted protein clones, providing a unique screening tool for discovering primary target receptors and assessing potential off-target binding issues.

The combination of Retrogenix's capabilities with Distributed Bio's large-molecule discovery platform will further strengthen Charles River's integrated, end-to-end solution for therapeutic antibody and cell and gene therapy discovery and development.

Charles River has also formed a strategic partnership with Valence Discovery, gaining access to their artificial intelligence (AI) platform for molecular property prediction, generative chemistry, and multiparameter optimization.